Hypertrophic Cardiomyopathy (HCM): Clinical Trials

1 enrolling by invitation, 1 recruiting. 2 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	2	Enrolling by invitation 1, Recruiting 1

Follow Hypertrophic Cardiomyopathy (HCM): new trials by email Literature Review of Hypertrophic Cardiomyopathy (HCM) trials Research Report on Hypertrophic Cardiomyopathy (HCM)

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy Aficamten - Hypertrophic Cardiomyopathy (HCM)	Phase 4	Recruiting	Oregon Health and Science University	40	2026-05-05	2026-05-20
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction mavacamten, Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, diltiazem - Hypertrophic Cardiomyopathy (HCM)	Phase 4	Enrolling by invitation	Second Affiliated Hospital, Zhejiang University, School of Medicine	132	2026-03-01	2026-09-15

Narrower conditions

Cardiomyopathy, Hypertrophic (2)

Broader conditions

Aortic Stenosis, Subvalvular (2)  ·  Aortic Valve Disease (2)  ·  Aortic Valve Stenosis (2)  ·  Cardiomyopathies (2)  ·  Cardiovascular Diseases (2)  ·  Heart Diseases (2)  ·  Heart Valve Diseases (2)

Interventions

Adrenergic beta-Antagonists (1)  ·  Bisoprolol (1)  ·  Carvedilol (1)  ·  Diltiazem (1)  ·  MYK-461 (1)  ·  Metoprolol (1)

Sponsors

Oregon Health and Science University (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)

Countries

China (1)  ·  United States (1)